After the identification of the interleukin (IL)-1 type II receptor as the prototype, decoy receptors have been identified for a number of members of the IL-1/IL-18, TNF, IL-10 and IL-13 receptor families. Moreover, the silent receptor D6 is a promiscuous decoy and scavenger receptor of inflammatory chemokines. The IL-1 decoy receptor is regulated by pro- and anti-inflammatory signals and its levels may serve as a readout of the activation of anti-inflammatory pathways, for instance by glucocorticoid hormones. Decoy receptors represent a strategy to tune inflammatory and polarized adaptive responses.

Keywords:
Decoy receptors, Inflammation, Adaptive immunity, Interleukin-1, Chemokines
1.
Colotta F, Re F, Muzio M, Bertini R, Polentarutti N, Sironi M, Giri JG, Dower SK, Sims JE, Mantovani A: Interleukin-1 type II receptor: A decoy target for IL-1 that is regulated by IL-4. Science 1993;261:472–475.
2.
Colotta F, Dower SK, Sims JE, Mantovani A: The type II ‘decoy’ receptor: Novel regulatory pathway for interleukin-1. Immunol Today 1994;15:562–566.
3.
Mantovani A, Locati M, Vecchi A, Sozzani S, Allavena P: Decoy receptors: A strategy to regulate inflammatory cytokines and chemokines. Trends Immunol 2001;22:328–336.
4.
Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, Faggioni R, Luini W, vanHinsbergh V, Sozzani S, Bussolino F, Poli V, Ciliberto G, Mantovani A: Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997;6:315–325.
5.
Re F, Muzio M, De Rossi M, Polentarutti N, Giri JG, Mantovani A, Colotta F: The type II ‘receptor’ as a decoy target for IL-1 in polymorphonuclear leukocytes: Characterization of induction by dexamethasone and ligand binding properties of the released decoy receptor. J Exp Med 1994;179:739–743.
6.
Re F, Sironi M, Muzio M, Matteucci C, Introna M, Orlando S, Penton-Rol G, Dower SK, Sims JE, Colotta F, Mantovani A: Inhibition of interleukin-1 responsiveness by type II receptor gene transfer: A surface ‘receptor’ with anti-interleukin-1 function. J Exp Med 1996;183:1841–1850.
7.
Bossu P, Visconti U, Ruggiero P, Macchia G, Muda M, Bizzarri C, Colagrande A, Sabbatini V, Maurizi G: Transfected type II interleukin-1 receptor impairs responsiveness of human keratinocytes to interleukin-1. Am J Pathol 1995;147:1852–1861.
8.
Penton-Rol G, Polentarutti N, Sironi M, Saccani S, Introna M, Mantovani A: Gene transfer-mediated expression of physiological numbers of the type II decoy receptor in a myelomonocytic cellular context dampens the response to interleukin-1. Eur Cytokine Netw 1997;8:265–269.
9.
Bessis N, Guery L, Mantovani A, Vecchi A, Sims JE, Fradelizi D, Boissier MC: The type II decoy receptor of IL-1 inhibits murine collagen-induced arthritis. Eur J Immunol 2000;30:867–875.
10.
Lang D, Knop J, Wesche H, Raffetseder U, Kurrle R, Boraschi D, Martin MU: The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: A novel mechanism of regulation of IL-1 responsiveness. J Immunol 1998;161:6871–6877.
11.
Malinowsky D, Lundkvist J, Layé S, Bartfai T: Interleukin-1 receptor accessory protein interacts with the type II interleukin-1 receptor. FEBS Lett 1998;429:299–302.
12.
Smith DE, Hanna R, Della F, Moore H, Chen H, Farese AM, MacVittie TJ, Virca GD, Sims JE: The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity 2003;18:87–96.
13.
Bourke E, Cassetti A, Villa A, Fadlon E, Colotta F, Mantovani A: IL-1beta scavenging by the type II IL-1 decoy receptor in human neutrophils. J Immunol 2003;170:5999–6005.
14.
Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M: Interleukin-18 binding protein: A novel modulator of the Th1 cytokine response. Immunity 1999;10:127–136.
15.
Born TL, Morrison LA, Esteban DJ, VandenBos T, Thebeau LG, Chen N, Spriggs MK, Sims JE, Buller RM: A poxvirus protein that binds to and inactivates IL-18, and inhibits NK cell response. J Immunol 2000;164:3246–3254.
16.
Ashkenazi A: Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002;2:420–430.
17.
Kong YY, Boyle WJ, Penninger JM: Osteoprotegerin ligand: A regulator of immune responses and bone physiology. Immunol Today 2000;21:495–502.
18.
Ashkenazi A, Dixit VM: Death receptors: Signaling and modulation. Science 1998;281:1305–1308.
19.
Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ: Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997;89:309–319.
20.
Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165–176.
21.
Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami AT, Morinaga T, Higashio K: Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998;139:1329–1337.
22.
Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, Ozawa H: Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998;247:610–615.
23.
Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260–1268.
24.
Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818–821.
25.
Nagata S: Steering anti-cancer drugs away from the TRAIL. Nat Med 2000;6:502–503.
26.
Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, Strom SC: Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000;6:564–567.
27.
Jenkins M, Keir M, McCune JM: A membrane-bound Fas decoy receptor expressed by human thymocytes. J Biol Chem 2000;275:7988–7933.
28.
Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, Godowski PJ, Wood WI, Gurney AL, Hillan KJ, Cohen RL, Goddard AD, Botstein D, Ashkenazi A: Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998;396:699–703.
29.
Yu KY, Kwon B, Ni J, Zhai Y, Ebner R, Kwon BS: A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem 1999;274:13733–13736.
30.
Dumoutier L, Lejeune D, Colau D, Renauld JC: Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22. J Immunol 2001;166:7090–7095.
31.
Kotenko SV, Izotova LS, Mirochnitchenko OV, Esterova E, Dickensheets H, Donnelly RP, Pestka S: Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity. J Immunol 2001;166:7096–7103.
32.
Chiaramonte MG, Mentink-Kane M, Jacobson BA, Cheever AW, Whitters MJ, Goad ME, Wong A, Collins M, Donaldson DD, Grusby MJ, Wynn TA: Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response. J Exp Med 2003;197:687–701.
33.
Wood N, Whitters MJ, Jacobson BA, Witek J, Sypek JP, Kasaian M, Eppihimer MJ, Unger M, Tanaka T, Goldman SJ, Collins M, Donaldson DD, Grusby MJ: Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2. J Exp Med 2003;197:703–709.
34.
Liu C, Hart RP, Liu X-J, Clevenger W, Maki RA, De Souza EB: Cloning and characterization of an alternatively processed human type II interleukin-1 receptor mRNA. J Biol Chem 1996;271:20965–20972.
35.
Orlando S, Sironi M, Bianchi G, Drummond AH, Boraschi D, Yabes D, Colotta F, Mantovani A: Role of the metalloproteases in the release of the IL-1 type II decoy receptor. J Biol Chem 1997;272:31764–31769.
36.
Orlando S, Polentarutti N, Mantovani A: Selectivity release of the type II decoy IL-1 receptor. Cytokine 2000;12:1001–1006.
37.
Daun JM, Ball RW, Burger HR, Cannon JG: Aspirin-induced increases in soluble IL-1 receptor type II concentrations in vitro and in vivo. J Leukoc Biol 1999;65:863–866.
38.
Pruitt JH, Welborn MB, Edwards PD, Harward TR, Seeger JW, Martin TD, Smith C, Kenney JA, Wesdorf RI, Meijer S, Cuesta MA, Abouhanze A, Copeland EM III, Giri JG, Moldawer LL, Oldenburg HS: Increased soluble interleukin-1 type II receptor concentrations in postoperative patients and in patients with sepsis syndrome. Blood 1996;87:3282–3288.
39.
Barak V, Nisman B, Polliack A, Vannier E, Dinarello CA: Correlation of serum levels of interleukin-1 family members with disease activity and response to treatment in hairy cell leukemia. Eur Cytokine Netw 1998;9:33–39.
40.
van Deuren M, van der Ven-Jongekrijg J, Vannier E, van Dalen R, Pesman G, Bartelink AKM, Dinarello CA, van der Meer JWM: The pattern of interleukin-1β (IL-1β) and its modulating agents IL-1 receptor antagonist and IL-1 soluble receptor type II in acute meningococcal infections. Blood 1997;90:1101–1108.
41.
van der Poll T, de Waal Malefyt R, Coyle SM, Lowry SF: Antiinflammatory cytokine responses during clinical sepsis and experimental endotoxemia: Sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10, and IL-13. J Infect Dis 1997;175:118–122.
42.
Vannier E, Kaser A, Atkins MB, Fantuzzi G, Dinarello CA, Mier JW, Tilg H: Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy. Eur Cytokine Netw 1999;10:37–42.
43.
Mantovani A, Muzio M, Garlanda C, Sozzani S, Allavena P: Macrophage control of inflammation: Negative pathways of regulation of inflammatory cytokines; in: Chronic Obstructive Pulmonary Disease: Pathogenesis to Treatment. Chichester, Wiley, 2001, pp 120–131.
44.
Muller B, Peri G, Doni A, Torri V, Landmann R, Bottazzi B, Mantovani A: Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med 2001;29:1404–1407.
45.
Dentener MA, Creutzberg EC, Schols AM, Mantovani A, van’t Veer C, Buurman WA, Wouters EF: Systemic anti-inflammatory mediators in COPD: Increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax 2001;56:721–726.
46.
Arend WP, Malyak M, Smith MFJ, Whisenand TD, Slack JL, Sims JE, Giri JG, Dower SK: Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J Immunol 1994;153:4766–4774.
47.
Attur MG, Dave M, Cipolletta C, Kang P, Goldring MB, Patel IR, Abramson SB, Amin AR: Reversal of autocrine and paracrine effects of interleukin 1 (IL-1) in human arthritis by type II IL-1 decoy receptor. Potential for pharmacological intervention. J Biol Chem 2000;275:40307–40315.
48.
D’Amico G, Frascaroli G, Bianchi G, Transidico P, Doni A, Vecchi A, Sozzani S, Allavena P, Mantovani A: Uncoupling of inflammatory chemokine receptors by IL-10:Generation of functional decoys. Nat Immunol 2000;1:387–391.
49.
Bleul CC, Schultze JL, Springer TA: B lymphocyte chemotaxis regulated in association with microanatomic localization, differentiation state, and B cell receptor engagement. J Exp Med 1998;187:753–762.
50.
Liao F, Rabin RL, Smith CS, Sharma G, Nutman TB, Farber JM: CC-chemokine receptor 6 is expressed on diverse memory subsets of T cells and determines responsiveness to macrophage inflammatory protein 3 alpha. J Immunol 1999;162:186–194.
51.
Sozzani S, Luini W, Borsatti A, Polentarutti N, Zhou D, Piemonti L, D’Amico G, Power CA, Wells TN, Gobbi M, Allavena P, Mantovani A: Receptor expression and responsiveness of human dendritic cells to a defined set of CC and CXC chemokines. J Immunol 1997;159:1993–2000.
52.
Bonecchi R, Facchetti F, Dusi S, Luini W, Lissandrini D, Simmelink M, Locati M, Bernasconi S, Allavena P, Brandt E, Rossi F, Mantovani A, Sozzani S: Induction of functional IL-8 receptors by IL-4 and IL-13 in human monocytes. J Immunol 2000;164:3862–3869.
53.
Penna G, Sozzani S, Adorini L: Cutting edge: Selective usage of chemokine receptors by plasmacytoid dendritic cells. J Immunol 2001;167:1862–1866.
54.
Caux C, Vanberliet B, Massacrier C, Dezutter-Dambuyant C, de Saint-Vis B, Jacquet C, Yoneda K, Imamura S, Schmitt D, Bancherau J: CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNFα. J Exp Med 1996;184:695–706.
55.
Krug A, Uppaluri R, Facchetti F, Dorner BG, Sheehan KC, Schreiber RD, Cella M, Colonna M: IFN-producing cells respond to CXCR3 ligands in the presence of CXCL12 and secrete inflammatory chemokines upon activation. J Immunol 2002;169:6079–6083.
56.
Nibbs RJ, Kriehuber E, Ponath PD, Parent D, Qin S, Campbell JD, Henderson A, Kerjaschki D, Maurer D, Graham GJ, Rot A: The beta-chemokine receptor D6 is expressed by lymphatic endothelium and a subset of vascular tumors. Am J Pathol 2001;158:867–877.
57.
Fra AM, Locati M, Otero K, Sironi M, Signorelli P, Massardi MI, Gobbi M, Vecchi A, Sozzani S, Mantovani A: Cutting edge: Scavenging of inflammatory CC chemokines by the promiscuous putatively silent chemokine receptor D6. J Immunol 2003;170:2279–2282.
58.
Bonecchi R, Locati M, Vulcano M, Sironi M, Fra AM, Gobbi M, Vecchi A, Sozzani S, Van Damme J, Mantovani A: Differential recognition and scavenging of native and truncated macrophage-derived chemokine MDC/CCL22 by the D6 chemokine decoy receptor. J Immunol 2003, in press
59.
Proost P, Struyf S, Schols D, Opdenakker G, Sozzani S, Allavena P, Mantovani A, Augusuns K, Bal G, Haemers A, Lambeir AM, Scharpé S, Van Damme J, De Meester I: Truncation of macrophage-derived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affect chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem 1999;274:3988–3999.
60.
Struyf S, Proost P, Sozzani S, Mantovani A, Wuyts A, De Clercq E, Schols D, Van Damme J: Cutting edge: Enhanced anti-HIV-1 activity and altered chemotactic potency of NH2-terminally processed macrophage-derived chemokine (MDC) imply an additional MDC receptor. J Immunol 1998;161:2672–2675.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.